Advice

following a full submission:

liraglutide (Saxenda®) is not recommended for use within NHSScotland.

Indication under review: as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of:

  • ≥30kg/m² (obese), or
  • ≥27kg/m² to <30kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea

In a phase III study, liraglutide, as an adjunct to diet and exercise, was associated with significantly reduced body weight compared with placebo in patients with BMI ≥30kg/m2 or ≥27kg/m2 if they had dyslipidaemia or hypertension.

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Medicine details

Medicine name:
liraglutide (Saxenda)
SMC ID:
SMC2378
Indication:

As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of

  • ≥30 kg/m² (obese), or
  • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.
Pharmaceutical company
Novo Nordisk Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Not recommended
Date advice published
11 October 2021